Process for removing growth factors from platelets
A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure.
1. A process for obtaining growth factors comprising the steps of:
providing a preselected quantity of unfrozen growth factor starting material, wherein the unfrozen growth factor starting material is obtained from the tissue of a subject,
applying a preselected sub-atmospheric pressure to the unfrozen growth factor starting material sufficient to release growth factors from the unfrozen growth factor starting material without activating the growth factor starting material,
collecting the released growth factors in a bioactive state for mixture with a nondestructive medium without dehydrating the growth factor starting material, and
providing in the nondestructive medium a therapeutically effective amount of growth factors for having a positive reaction on living tissue.
2. A process as set forth in claim 1 which includes:
selecting the growth factor starting material from the group consisting of whole blood, platelet rich plasma, platelet poor plasma, bone marrow, umbilical cord fluid, and combinations thereof.
3. A process as set forth in claim 1 which includes:
providing unfrozen growth factor starting material having a combination of platelet rich plasma and platelet poor plasma.
4. A process as set forth in claim 1 which includes:
providing unfrozen growth factor starting material having platelets.
5. A process as set forth in claim 1 wherein collecting includes:
filtering the released growth factors from other components within the unfrozen growth factor starting material.
6. A process as set forth in claim 5 which includes:
filtering the released growth factors using a 0.2 micron filter.
7. A process as set forth in claim 1 which includes:
providing unfrozen growth factor starting material having platelet rich plasma, and
releasing the growth factors from the platelets in the platelet rich plasma to provide a wound healing composition having the plasma and the growth factors.
8. A process as set forth in claim 1 which includes:
lyophilizing the released growth factors to provide a shelf-stable product for preserving the growth factors for bioactive use.
9. A process as set forth in claim 8 which includes:
mixing the shelf-stable product with a sterile solution to reconstitute the lyophilized growth factors prior to use in a wound healing application.
10. A process as set forth in claim 1 which includes:
mixing a preselected pharmaceutical agent with the released growth factors.
11. A process as set forth in claim 10 which includes:
lyophilizing the mixture of the preselected pharmaceutical agent and released growth factors to preserve the mixture for subsequent bioactive use.
12. A process as set forth in claim 11 which includes:
reconstituting the lyophilized mixture of preselected pharmaceutical agent and released growth factors with a preselected amount of 0.9% saline solution.
13. A process as set forth in claim 1 which includes:
applying a sub-atmospheric pressure to the growth factor starting material in the range between about 1 atmosphere to 5 millibars.
14. A process as set forth in claim 13 which includes:
applying the sub-atmospheric pressure at a temperature above 1° C.
15. A process for obtaining growth factors for application in wound healing procedures comprising the steps of:
providing a preselected quantity of whole blood containing unfrozen growth factor starting material,
applying a preselected sub-atmospheric pressure to the whole blood sufficient to release growth factors from the unfrozen growth factor starting material at a temperature above 1° C. without dehydrating the growth factor starting material,
collecting the released growth factors in a bioactive state for mixture with a nondestructive medium without activating the growth factor starting material, and
filtering the released growth factors for separation from platelets, bacteria, red blood cells, white blood cells, and other cellular debris.
16. A process as set forth in claim 15 which includes:
freeze drying the filtered growth factors to create a shelf-stable product preserved for subsequent bioactive use.
17. A process as set forth in claim 16 which includes:
mixing the self-stable product with a preselected material for hydrating the self-stable product for a therapeutic use.
18. A process as set forth in claim 17 which includes:
hydrating the shelf-stable product with a 0.9% saline solution.
19. A process as set forth in claim 16 which includes:
adding a preselected pharmaceutical agent to the filtered growth factors prior to the step of freeze drying.
20. A process as set forth in claim 15 which includes:
topically applying the filtered growth factors to a wound for healing the wound.
21. A process as set forth in claim 15 which includes:
injecting the filtered growth factors in damaged soft tissue to heal the soft tissue.
22. A process as set forth in claim 1 which further includes:
separating the released growth factors from the growth factor starting material to form a first therapeutic composition that is substantially free of growth factors from the growth factor starting material, then mix the therapeutically effective amount of growth factors with the nondestructive medium to form a second therapeutic composition.
23. A process as set forth in claim 22 which includes:
selecting the growth factor starting material from the group consisting of whole blood, platelet rich plasma, platelet poor plasma, bone marrow, umbilical cord fluid, and combinations thereof.
24. A process as set forth in claim 22 which includes:
providing unfrozen growth factor starting material having a combination of platelet rich plasma and platelet poor plasma.
25. A process as set forth in claim 22 which includes:
providing unfrozen growth factor starting material having platelets.
26. A process as set forth in claim 22 which includes:
separating the released growth factors from other components within the unfrozen growth factor starting material by filtering.
27. A process as set forth in claim 22 which includes:
the unfrozen growth factor starting material comprises platelet rich plasma with platelets therein.